ARD-101 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 193 | プラダー・ウィリ症候群 | 1 |
193. プラダー・ウィリ症候群
臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05153434 (ClinicalTrials.gov) | March 24, 2022 | 30/11/2021 | A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome | A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | Drug: ARD-101 | Aardvark Therapeutics, Inc. | Children's Hospital Colorado | Recruiting | 17 Years | 65 Years | All | 12 | Phase 2 | United States |